Bruker Corporation (BRKR) Fair Value 2026

BRKR · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.5 /10

32 fundamental signals · 8 models active

Value Trap Risk

WARN (43/100)

Quick Summary — As of 2026-10-07, Bruker Corporation (BRKR) trades at $60.50, versus a $18.75 median fair value across its 8 active models — 69.0% below the current price. QOC: 7.5/10. Value Trap Risk: 43/100 (WARN). 8/13 models active.

Key Facts

Ticker
BRKR
Price
$60.50
Quality Score
7.5/10
Value Trap Risk
43/100
Models Active
8/13
Last Updated
Strength: 8 independent models provide multi-angle coverage
Risk: Value Trap score of 43 suggests caution despite apparent undervaluation

Is Bruker Corporation (BRKR) Undervalued or Overvalued in 2026?

According to CirclFi’s 8-model valuation engine, Bruker Corporation (BRKR) appears overvalued as of : the median of 8 independent fair value estimates is $18.75, 69.0% below the current price of $60.50. Estimates range from $1.12 to $74.64. BRKR scores 7.5/10 on fundamental quality and 43/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -20.1% versus its own 13-model consensus, across 3,777 rated companies as of 2026-10-07. BRKR’s -69.0% gap is wider than that market norm, and the Medical Devices sector median is -41.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Bruker Corporation Stock in 2026? →

What Fair Value Does Each Model Give BRKR?

8 Intrinsic Value Models vs. Current Price ($60.50)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $11.99 -80.2%
Ensemble · Low Conviction
 $18.92 -68.7%
Scenario · High Conviction
 $22.36 -63.0%
Intrinsic · High Conviction
 $16.93 -72.0%
Unlock the Full Matrix

Access 4 additional models including ML-RIV, Regime Cross-Sectional, and more.

$2 / day

Billed monthly ($60/mo) or annually ($299/yr)

Unlock All 8 Models →

Cancel anytime · No contracts · Instant access

What Is BRKR's Fair Value Range?

Spread across 8 independent models · $1.12 to $74.64

CirclFi's 8 active models place Bruker Corporation (BRKR) between $1.12 and $74.64 per share, a spread of 392% of the median. The median of that range — $18.75 — is the fair value CirclFi publishes for BRKR, against a current price of $60.50.

Low · ML-RIVHigh · Regime Cross
$1.12median $18.75$74.64
Where the range comes from
Most bearish modelML Residual Income$1.12
Most bullish modelRegime Cross-Sectional$74.64
Model agreement1 bullish · 7 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for BRKR. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on BRKR, not a CirclFi price target. How each model works →

What Is Bruker Corporation (BRKR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Bruker Corporation's intrinsic value is estimated at $18.75, suggesting the stock is overvalued at its current price of $60.50. With 7 out of 8 models flagging downside (-69.0% vs price), the market may be pricing in unsustainable growth. Model dispersion is worth noting: Regime Cross targets $74.64 (+23.4%), versus ML-RIV at $1.12 (-98.1%). This +121.5% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About BRKR?

8 of 13 models are currently active for BRKR. Of these, 1 model suggests upside while 7 models suggest overvaluation. Taken together, their median fair value for BRKR is $18.75 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does BRKR Rank in Medical Devices?

Among 161 Medical Devices stocks, BRKR ranks #35 by Quality of Company score. CirclFi's QOC score of 7.5/10 evaluates 32 fundamental signals. A score of 7.5 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

As a biopharma enterprise, Bruker Corporation operates in a sector where revenue per drug is a critical driver of valuation. Investors evaluating BRKR should weigh these sector-specific dynamics alongside our model-derived fair values.

Is BRKR a Value Trap?

CirclFi's Value Trap algorithm assigns BRKR a score of 43/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

8 of 13 models are active for Bruker Corporation. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Bruker Corporation's fundamental quality profile registers 7.5/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +121.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BRKR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BRKR's 8 active models, average confidence is 42%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Bruker Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

AXGNAxogen, Inc.QOC 7.6SIBNSI-BONE, Inc.QOC 7.5TXG10x Genomics, Inc.QOC 7.6DCTHDelcath Systems, Inc.QOC 7.4BIOBio-Rad Laboratories, Inc.QOC 7.8SNWVSANUWAVE Health, Inc.QOC 7.4BFLYButterfly Network, Inc.QOC 6.4LUCDLucid Diagnostics Inc.QOC 5.5RTGNRetinalGenix Technologies Inc.QOC 3.5IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: AXGN · SIBN · TXG · DCTH · BIO · SNWV · BFLY · LUCD · RTGN · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to BRKR?

7 companies across all industries closest to BRKR’s Quality of Company score of 7.5/10.

PMTSCPI Card Group Inc.QOC 7.6SUNSSunrise Realty Trust, Inc.QOC 7.5TSNTyson Foods, Inc.QOC 7.6CBUCommunity Financial System, Inc.QOC 7.5PWPPerella Weinberg PartnersQOC 7.6MNSBMainStreet Bancshares, Inc.QOC 7.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PMTS · SUNS · TSN · CBU · PWP · MNSB · NVDA

Where Does BRKR Sit in CirclFi's Medical Devices Rankings?

BRKR is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Bruker Corporation’s Valuation?

What is Bruker Corporation's intrinsic value in 2026?

CirclFi puts Bruker Corporation (BRKR)'s intrinsic value at $18.75 — the median of 8 independent model estimates as of 2026-10-07, ranging from $1.12 to $74.64. The Quality of Company score is 7.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BRKR overvalued or undervalued right now?

At $60.50, 1 of 8 active models suggest BRKR may be undervalued, while 7 indicate potential overvaluation. The median of all 8 fair value estimates is $18.75, 69.0% below the current price of $60.50 — a consensus view that BRKR is overvalued. The assessment depends on which methodology best fits Bruker Corporation's business model in Medical Devices.

What does a Quality of Company score of 7.5 mean for BRKR?

Bruker Corporation's QOC of 7.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on BRKR?

CirclFi analyzes BRKR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 8 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on BRKR?

Of the 8 models currently active on BRKR, Regime Cross-Sectional is the most bullish at $74.64 per share, and ML Residual Income is the most bearish at $1.12. CirclFi's published fair value for BRKR is the median of that range, $18.75, not either extreme. The gap between the two ends equals 392% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is BRKR a value trap in 2026?

Bruker Corporation's Value Trap score is 43/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries.

Cite this analysis — “According to CirclFi’s 8-model valuation engine, Bruker Corporation (BRKR) has a median fair value of $18.75 — 69.0% below the current price of $60.50 — as of 2026-10-07.” Source: circlfi.com/stock/BRKR/ · Methodology
Primary sources for this BRKR valuation
  • Financial statements: Bruker Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001109354) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BRKR as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 8 mathematical frameworks give you clarity on BRKR.

Unlock All 8 Fair Values — $60/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for BRKR Unlock All 8 — $60/mo